title: Response to Crizotinib and Clinical Outcome in ALK-Rearranged Pulmonary Pleomorphic Carcinoma.
authors.affiliation: Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan. Electronic address: konyasu222@gmail.com.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Murakami
authors.affiliation: Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Saka
authors.affiliation: Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan.
authors.forename: Masahide
authors.initials: M
authors.lastname: Oki
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary; D002277:Carcinoma / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D000077547:Crizotinib; D017809:Fatal Outcome; D015321:Gene Rearrangement; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D019233:Retreatment
chemical_list: D000970:Antineoplastic Agents; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases